The advancement of gene therapy is changing expectations for surgical training, particularly in highly specialised fields such as ophthalmology. Treatments such as Luxturna have shown how targeted science can move beyond laboratory progress and into procedures that demand exceptional clinical precision.
Fundamental XR is positioning itself around that requirement. The company’s immersive HapticVR technology is designed to help clinicians practise complex procedures in a simulated environment before entering the operating theatre. Breakthrough treatments may create clinical opportunity, but their value depends partly on whether healthcare systems can train enough specialists to deliver them safely, consistently and at scale.
Traditional surgical training can be constrained by access to expert supervision, operating room time, patient availability and geographic limitations. Simulation offers a way to reduce those constraints by allowing repeated practice, structured feedback and a more standardised route to capability. For companies operating in advanced therapies, medical devices and specialist care, this can support faster deployment, lower training friction and a clearer pathway from innovation to clinical use.
Fundamental XR’s approach sits at the intersection of several structural healthcare trends. Precision medicine is increasing procedural complexity. Healthcare systems are under pressure to improve efficiency. MedTech companies need to support product adoption beyond launch. Training, therefore, becomes more than an educational function. It becomes part of commercial execution, risk management and market readiness.
The company’s focus on immersive simulation gives it a role in bridging the gap between scientific progress and practical implementation. While new therapies can attract attention for their potential patient impact, the ability to prepare surgical teams may influence how widely and effectively those therapies can be delivered. By supporting repeatable and measurable training, Fundamental XR is aligning its platform with a recognised bottleneck in the healthcare innovation cycle.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
